As several cancer-targeted agents induce ferroptosis (Lei et al., 2022), molecular alterations in cadherin/catenin and/or Merlin-YAP signaling could serve as biomarkers predicting cancer cell responsiveness to ferroptosis-inducing therapies. This evidence concerns the gene NF2 and cancer.